ER22 / 23EK polymorphisms of the glucocorticoid receptor are not associated with the response of alcohol‐associated hepatitis patients to prednisolone treatment
Physiological Reports · 2026-11 · 14 (21)
DOI: 10.14814/phy2.71163 ↗Abstract
Abstract The effects of prednisolone on biochemical parameters in patients with alcohol‐associated hepatitis (AH) have been reported. However, data on the pharmacogenetic determinants of prednisolone response in these patients remain limited. Because the ER22/23EK polymorphism of the glucocorticoid receptor gene (NR3C1) has been linked with relative glucocorticoid resistance in other settings, this study investigated its prevalence and influence among prednisolone‐responsive and non‐responsive AH patients. A total of 134 patients with AH were enrolled in this prospective study. Biochemical parameters diagnostic of liver function, messenger ribonucleic acid (mRNA) expression of tumor necrosis factor‐alpha (TNF‐α), and ER22/23EK (rs6189 and rs6190) genotypes were assessed. Prednisolone response was defined using the Lille score after 7 days of therapy. Beyond classical biochemical parameters of liver function and the Lille score, ER22/23EK genotype polymorphisms of the glucocorticoid receptor were not associated with patients' response to prednisolone treatment in this cohort. TNF‐α mRNA expression was higher in AH patients who responded to prednisolone than in those who did not respond to treatment. TNF‐α mRNA was higher at day 7 among prednisolone responders than non‐responders. More importantly, in this cohort, prednisolone response among AH patients was not statistically associated with the ER22/23EK genotype. These findings should be interpreted cautiously because additional glucocorticoid receptor targets, 11β‐hydroxysteroid dehydrogenase expression, and functional GR assays were not assessed.
EUVIMED